title: Ketogenic diet treatment in adults with refractory epilepsy: a prospective pilot study.
abstract: OBJECTIVE
  To assess the efficacy of ketogenic diet (KD) in adults with refractory epilepsy.
  
  
  METHODS
  Eligible subjects were 18-45 years old with at least two monthly focal seizures (with or without secondary generalization) documented by 8 weeks' follow-up. Classic form of KD treatment (90% fat) was planned for 12 weeks: daily seizure diaries were kept and measurements of the urinary ketones were recorded. Blood studies were done monthly and resting energy expenditure (REE), substrate utilization; body composition and quality of life (QOL) were measured before and after intervention.
  
  
  RESULTS
  Nine patients were enrolled (average age 28+/-6 years; seven women). Only two subjects concluded the study per protocol due to an early drop-out. The average length of KD treatment was 8+/-4 weeks (two patients completed 12 weeks of KD; feelings of hunger and lack of efficacy resulted in withdrawal of the rest). The two patients who concluded the study had a more than 50% reduction in the frequency of the seizures. The others experienced no improvement. Adherence to the KD protocol (100%) was documented by constant ketonuria and increased fat utilization as indicated by the change in respiratory quotient (p<0.031). The KD increased the cholesterol levels (mainly LDL; p=0.0001).
  
  
  CONCLUSIONS
  In our experience with relatively small adult population, adherence to KD is difficult. In patients who had compliance over 3 weeks (6/8), KD does not seem to have a significant effect. Yet, the significant reduction in the two patients who concluded the study per protocol may indicate that some patients may benefit from this diet. Significant increase in LDL levels and the unlikable dietary changes are additional impediments to its implementation among adults with refractory epilepsy.
authors.affiliation: The Headache Clinic of the Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. mosek@tasmc.health.gov.il
authors.forename: Amnon
authors.initials: A
authors.lastname: Mosek
authors.forename: Haitham
authors.initials: H
authors.lastname: Natour
authors.forename: Miri Y
authors.initials: MY
authors.lastname: Neufeld
authors.forename: Yaffa
authors.initials: Y
authors.lastname: Shiff
authors.forename: Nachum
authors.initials: N
authors.lastname: Vaisman
mesh_terms: D015502:Absorptiometry, Photon; D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D055423:Diet, Ketogenic / Q000379:methods*; D004827:Epilepsy / Q000178:diet therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D050356:Lipid Metabolism; D008099:Liver / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D011788:Quality of Life; D055815:Young Adult